News

Argatroban Intravenous for Adults

Who can administer

May be administered by registered competent doctor or nurse/midwife

Important information

  • Ordered on advice of consultant haematologist only
  • Unlicensed preparation in Ireland
  • IMPORTANT: The ACT is NOT the same as the aPTT. Results are not interchangeable.
  • See under Dose for adjustments required in renal or hepatic impairment

Available preparations

Exembol 250mg per 2.5ml vial (contains ethanol 1g / 2.5ml vial)

Reconstitution

  • Already in solution
  • Dilute further prior to administration

Infusion fluids

  • Sodium chloride 0.9% or Glucose 5%
  • Mix by repeated inversion of the infusion bag for 1 minute

Methods of intravenous administration

Continuous intravenous infusion (administer using an electronically controlled infusion device)

  • Add 250mg (2.5ml) vial to 250ml infusion fluid (no need to remove 2.5ml from bag)
  • Using a 1mg per ml solution (250mg in 250ml) - set up the continuous infusion
  • Adjust dose as per 'Dose'

Slow intravenous injection (Percutaneous intervention only, see dose under Further Information)

  • Given over 3 to 5 minutes

Dose in adults

Heparin induced thrombocytopenia (HIT)

  • All patients with HIT must be managed in conjunction with haematology
  • If baseline aPTT elevated- discuss target aPTT with Haematology
  • APTTr; the patient's activated partial thromboplastin time divided by either the laboratory's normal value or the patient's own baseline value
  • Prior to commencement stop heparin and take baseline aPTT, PT and fibrinogen (CLAUSS) (ref 1)
  • Argatroban is a direct thrombin inhibitor. Its anticoagulant effect is measured by the APTTr and INR, which increase in a dose dependent manner. Dose adjustments are based on the APTTr as shown in the table below.
  • Daily monitoring is sufficient after 2 consecutive aPTT within target range if no dose adjustments were made (ref 1)
  • Argatroban interferes with the Clauss Fibrinogen assay resulting in falsely low results. The derived fibrinogen assay may be more reliable but both will be abnormal at higher argatroban concentrations(ref 1)
  • The lab MUST be informed that patient is receiving argatroban(ref 1)
Table 1: Recommended starting doses and monitoring intervals (see table 3 below for flow rates)
Argatroban dose (mcg/kg/minute) Interval to check aPTT after initial dose and each dose change thereafter

Standard dose

2 2 hours
Critically ill patients* 0.5 4 hours
Moderate hepatic impairment** 0.5 4 hours
* Multi-system organ failure, ICU patients, heart failure, post cardiac surgery, anasarca
** Moderate hepatic impairment (Child Pugh B)
Table 2: Dose modifications and monitoring intervals (see Table 3 below for flow rates)

Standard dosing schedule

Critically ill/Hepatically impaired patients

Initial infusion rate 2mcg/kg/minute Initial infusion rate 0.5mcg/kg/min
aPTT Infusion rate change Next aPTT Infusion rate change Next aPTT
<1.5 patient's baseline Increase by 0.5mcg/kg/min 2 hours Increase by 0.1mcg/kg/min 4 hours

1.5 to 3 times patient's baseline

(and less than 100 seconds)

No change

Ideal range: 1.5 to 2.5 patient's baseline aPTT as per Dr Gilmore

2 hours

After 2 consecutive aPTT within target range, check at least 24 hours

No change

4 hours

After 2 consecutive aPTT within target range, check at least every 24 hours

> 3 times patient's baseline or if over 100 seconds

Discontinue infusion until APTT is within desired range (typically within 2 hours of discontinuation) - restart at 50% of the previous rate

2 hours

Discontinue infusion until APTT is within desired range (typically within 2 hours of discontinuation) - restart at 50% of the previous rate

4 hours
  • The maximum recommended dose is 10 microgram/kg/minute
  • The maximum recommended duration of treatment is 14 days, although there is limited experience with administration for longer periods
Table 3: Infusion rate in ml/HOUR of a 1mg/1ml infusion
Dose/Weight (kg) 0.1micrograms/kg/min 0.5micrograms/kg/min 1micrograms/kg/min 2micrograms/kg/min
50 0.3 1.5 3 6
60 0.36 1.8 3.6 7.2
70 0.42 2.1 4.2 8.4
80 0.48 2.4 4.8 9.6
90 0.54 2.7 5.4 10.8
100 0.6 3 6 12
110 0.66 3.3 6.6 13.2
120 0.72 3.6 7.2 14.4
130 0.78 3.9 7.8 15.6
140 0.84 4.2 8.4 16.8
150 0.9 4.5 9 18

    Patients with HIT Type II undergoing percutaneous coronary intervention (PCI)

    • Limited data is available from the use of argatroban in patients with HIT Type II undergoing percutaneous coronary intervention
    • Based on the data, when there is no alternative, therapy could be initiated with a bolus dose of 350 microgram/kg over 3 to 5 minutes
    • This is followed by an infusion dose of 25 microgram/kg/min
    • ACT should be checked 5 to 10 minutes after the bolus dose is completed
    • The procedure may proceed if the ACT is greater than 300 seconds
    • If the ACT is below 300 seconds, an additional bolus dose of 150 microgram/kg should be administered, the infusion rate be increased to 30 microgram/kg/min, and the ACT should be checked 5 to 10 minutes later
    • If the ACT is higher than 450 seconds the infusion rate should be decreased to 15 microgram/kg/min and ACT values be checked 5 to 10 minutes later
    • Once a therapeutic ACT between 300 to 450 seconds has been achieved, the infusion dose should be continued for the duration of the procedure
    • ACT measurements were recorded using both Haemotec and Haemochrom devices
    • The efficacy and safety of argatroban use in combination with GPIIb/IIIa inhibitors has not been established.

    Renal impairment

    • No initial dosage adjustment necessary in mild to severe renal impairment. Monitor aPTT closely.
    • Haemodialysis: limited data. Consult haematologist and see specialist texts

    Liver impairment

    • Use with extreme caution in hepatic impairment
    • See Tables 1 and 2 above for doses
    • Reversal of the anticoagulant effects of argatroban may take longer in this setting (more than four hours)
    • Argatroban is contraindicated in patients with severe hepatic impairment

    Changing to oral anticoagulation (ref 1)

    • A Haematology Consultant (ideally with Special Interest in Coagulation) will decide on the timing, duration and choice of oral anticoagulant
    • Patients with HIT require a minimum of three months of oral anticoagulation
    • If starting DOAC
      • stop argatroban and start DOAC
      • Rivaroxaban, apixaban and dabigatran have all been used in this situation
    • If starting warfarin therapy for patient on argatroban
      • Warfarin should only be commenced when there is resolution of thrombocytopenia (to avoid coumarin-associated microvascular thrombosis and venous limb gangrene)
      • To avoid prothrombotic effects and to ensure continuous anticoagulation, argatroban must be continued during the initiation of warfarin therapy
      • A minimum overlap of argatroban and warfarin of at least 5 days is advised
      • Argatroban has a significant effect on the INR
      • NO loading doses of warfarin to be given
      • Start with the intended maintenance dose of warfarin (no greater than 5mg daily)
      • Discontinue argatroban when INR reaches up to 4 for at least two days, on COMBINED therapy (INR should be 2 greater than desired target range- eg in patients with target INR of 2 to 3, INR on combined argatroban and warfarin should be 4 to 5) (ref 3)
      • Repeat INR 4 to 6 hours after stopping argatroban, to ensure INR is therapeutic prior to permanent discontinuation of argatroban(ref 3)
      • If INR is below the desired therapeutic range recommence argatroban and repeat the procedure above (steps 2 to 6)
      • Take INR at least daily

    Monitoring

    • See above

    Storage

    • Store below 250C
    • Do not refrigerate or freeze
    • The diluted solution is stable for 24 hours if kept at 250C or less (do not expose the diluted solution to direct sunlight)

    References

    UK SPC (Exembol) 31/10/2024

    1. Dr Ruth Gilmore, Consultant Haematologist, 26/03/2025

    2. Heparin induced thrombocytopenia - a comprehensive clinical review, Salter et al. JACC Vol 67, No 21, 2016

    Therapeutic classification

    Parenteral anticoagulants

    IV Guide Type